These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9154500)

  • 41. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT.
    Zaccaro C; Saracino IM; Fiorini G; Figura N; Holton J; Castelli V; Pesci V; Gatta L; Vaira D
    Intern Emerg Med; 2017 Apr; 12(3):333-339. PubMed ID: 28155016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy.
    Parente F; Vailati C; Boemo C; Bonoldi E; Ardizzoia A; Ilardo A; Tortorella F; Cereda D; Cremaschini M; Moretti R
    Dig Liver Dis; 2015 Jan; 47(1):68-72. PubMed ID: 25306524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimation of the optimal cut off point in a new immunological faecal occult blood test in a corporate colorectal cancer screening programme.
    Itoh M; Takahashi K; Nishida H; Sakagami K; Okubo T
    J Med Screen; 1996; 3(2):66-71. PubMed ID: 8849762
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Faecal occult blood tests--eliminate, enhance or update?
    Fraser CG
    Ann Clin Biochem; 2008 Mar; 45(Pt 2):117-21. PubMed ID: 18325172
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening.
    Dekker N; van Rossum LG; Van Vugt-van Pinxteren M; van Stiphout SH; Hermens RP; van Zelst-Stams WA; van Oijen MG; Laheij RJ; Jansen JB; Hoogerbrugge N
    Eur J Cancer; 2011 Jul; 47(10):1571-7. PubMed ID: 21367600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improving the effectiveness of fecal occult blood testing in a primary care clinic by direct colonoscopy referral for positive tests.
    Van Kleek E; Liu S; Conn LM; Hoadley A; Ho SB
    J Healthc Qual; 2010; 32(6):62-9. PubMed ID: 20946427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of three faecal occult blood tests in the detection of colorectal neoplasia.
    Hope RL; Chu G; Hope AH; Newcombe RG; Gillespie PE; Williams SJ
    Gut; 1996 Nov; 39(5):722-5. PubMed ID: 9014773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Early detection of bowel cancer in occupational surveillance examinations: switching from a guaiak-based to an immunochemical fecal occult blood test].
    Webendörfer S; Riemann JF
    Dtsch Med Wochenschr; 2014 Jan; 139(3):79-83. PubMed ID: 24089288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reducing income-related inequities in colorectal cancer screening: lessons learned from a retrospective analysis of organised programme and non-programme screening delivery in Winnipeg, Manitoba.
    Decker KM; Demers AA; Nugent Z; Biswanger N; Singh H
    BMJ Open; 2016 Feb; 6(2):e009470. PubMed ID: 26908517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.
    Castiglione G; Grazzini G; Miccinesi G; Rubeca T; Sani C; Turco P; Zappa M
    J Med Screen; 2002; 9(3):99-103. PubMed ID: 12370319
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial.
    You JJ; Liu Y; Kirby J; Vora P; Moayyedi P
    Trials; 2015 Jul; 16():296. PubMed ID: 26156248
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Colorectal cancer screening behavior in women attending screening mammography: longitudinal trends and predictors.
    Carlos RC; Fendrick AM; Abrahamse PH; Dong Q; Patterson SK; Bernstein SJ
    Womens Health Issues; 2005; 15(6):249-57. PubMed ID: 16325138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A case-control study to evaluate efficacy of screening for faecal occult blood.
    Lazovich D; Weiss NS; Stevens NG; White E; McKnight B; Wagner EH
    J Med Screen; 1995; 2(2):84-9. PubMed ID: 7497161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-invasive detection of colorectal tumours by the combined application of molecular diagnosis and the faecal occult blood test.
    Kutzner N; Hoffmann I; Linke C; Thienel T; Grzegorczyk M; Urfer W; Martin D; Winde G; Traska T; Hohlbach G; Müller KM; Kuhnen C; Müller O
    Cancer Lett; 2005 Nov; 229(1):33-41. PubMed ID: 16157216
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uptake of a colorectal cancer screening blood test in people with elevated risk for cancer who cannot or will not complete a faecal occult blood test.
    Symonds EL; Cock C; Meng R; Cole SR; Fraser RJL; Young GP
    Eur J Cancer Prev; 2018 Sep; 27(5):425-432. PubMed ID: 28368949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal Cancer.
    Batty CA; Cauchi M; Lourenço C; Hunter JO; Turner C
    PLoS One; 2015; 10(6):e0130301. PubMed ID: 26086914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.